Anocca has Dosed First Patients with Precision TCR-T Cell Therapy Targeting Mutant KRAS in Pancreatic Cancer
City AM
—
Anocca AB (‘Anocca’ or the ‘Company’), a clinical-stage biotechnology company developing advanced T-cell immunotherapies, today announced the successful dosing of the first patients across multiple clinical sites with ANOC-001, a novel T cell receptor-modified T cell therapy (TCR-T)[1] targeting KRAS G12V mutations in an aggressive form of pancreatic cancer.
ANOC-001 is the first product to https://www.cityam.com/anocca-has-dosed-first-patients-with-precision-tcr-t-cell-therapy-targeting-mutant-kras-in-pancreatic-cancer/">[...]